Citadel Advisors
RNAC icon

Citadel Advisors’s Cartesian Therapeutics RNAC Stock Holding History

Citadel Advisors’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-110,128
Closed -$677K – 14673
2026
Q1 		$677K Buy
110,128
+30,343
+38% +$216K ﹤0.01% 8565
2025
Q4 		$575K Buy
79,785
+9,261
+13% +$74.9K ﹤0.01% 8689
2025
Q3 		$721K Sell
70,524
-50,350
-42% -$566K ﹤0.01% 8277
2025
Q2 		$1.26M Sell
120,874
-26,423
-18% -$281K ﹤0.01% 6601
2025
Q1 		$1.94M Sell
147,297
-167,703
-53% -$3M ﹤0.01% 5589
2024
Q4 		$5.64M Sell
315,000
-60,767
-16% -$1.23M ﹤0.01% 3763
2024
Q3 		$5.76M Buy
+375,767
New +$5.87M ﹤0.01% 3728
2024
Q2 		– Sell
-3,318
Closed -$64.7K – 15214
2024
Q1 		$64.7K Sell
3,318
-14,252
-81% -$302K ﹤0.01% 11916
2023
Q4 		$363K Sell
17,570
-1,585
-8% -$47.3K ﹤0.01% 8760
2023
Q3 		$609K Buy
19,155
+644
+3% +$21.5K ﹤0.01% 7626
2023
Q2 		$622K Buy
18,511
+1,588
+9% +$56.8K ﹤0.01% 7451
2023
Q1 		$706K Buy
16,923
+10,840
+178% +$510K ﹤0.01% 7547
2022
Q4 		$206K Sell
6,083
-22,184
-78% -$944K ﹤0.01% 10081
2022
Q3 		$1.39M Buy
28,267
+19,196
+212% +$1.05M ﹤0.01% 6309
2022
Q2 		$357K Sell
9,071
-1,140
-11% -$33.8K ﹤0.01% 9418
2022
Q1 		$377K Buy
10,211
+2,381
+30% +$149K ﹤0.01% 10062
2021
Q4 		$765K Buy
7,830
+4,368
+126% +$470K ﹤0.01% 8597
2021
Q3 		$432K Sell
3,462
-548
-14% -$66.2K ﹤0.01% 10239
2021
Q2 		$503K Sell
4,010
-2,832
-41% -$337K ﹤0.01% 10050
2021
Q1 		$929K Buy
6,842
+2,996
+78% +$372K ﹤0.01% 8305
2020
Q4 		$350K Buy
3,846
+3,277
+576% +$284K ﹤0.01% 8794
2020
Q3 		$42K Buy
+569
New +$43.6K ﹤0.01% 9661
2020
Q2 		– Sell
-56,511
Closed -$4.09M – 10397
2020
Q1 		$4.09M Buy
+56,511
New +$5.46M ﹤0.01% 2988
2019
Q1 		– Sell
-739
Closed -$59K – 9774
2018
Q4 		$59K Buy
+739
New +$169K ﹤0.01% 8447

Other funds holding RNAC

Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Citadel Advisors's RNAC Position: Q2 2026 in Review

Citadel Advisors sold out of Cartesian Therapeutics (RNAC) in Q2 2026, closing a stake of 110,128 shares — an estimated $677K sold.

Citadel Advisors first reported a position in RNAC in Q4 2018 and held it in 24 quarters. The position peaked at $5.76M in Q3 2024. 94 funds tracked by Wall St. Rank hold RNAC as of Q2 2026.

  • Citadel Advisors reported no remaining Cartesian Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Citadel Advisors sold 110,128 Cartesian Therapeutics shares in Q2 2026, an estimated $677K.
  • Citadel Advisors first reported a position in Cartesian Therapeutics in Q4 2018 and held it in 24 quarters.
  • Citadel Advisors's Cartesian Therapeutics position peaked at $5.76M in Q3 2024.
  • 94 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.